Perimenopause & Menopause

The hormonal transition of perimenopause and menopause significantly influences the lower urinary tract, vaginal tissues, and pelvic floor muscles. Understanding the physiological mechanisms of estrogen depletion empowers you to seek effective, evidence-based treatments for symptoms that are frequently misunderstood or normalized.

The Hormonal Shift: Estrogen and the Urogenital Tract

Estrogen receptors (both ER-alpha and ER-beta) are densely concentrated throughout the lower urogenital tract—including the urethra, bladder trigone, vaginal epithelium, pelvic fascia, and the levator ani muscle complex. As ovarian follicular activity declines during perimenopause and ceases at menopause, circulating levels of 17β-estradiol drop dramatically.

This hormonal withdrawal triggers profound physiological alterations:

Genitourinary Syndrome of Menopause (GSM)

In 2014, The Menopause Society (formerly NAMS) and the International Society for the Study of Women’s Sexual Health (ISSWSH) officially introduced the term Genitourinary Syndrome of Menopause (GSM) to replace older, narrower designations such as “vulvovaginal atrophy.” GSM encompasses a triad of progressive symptoms affecting over 50% of postmenopausal women:

Unlike vasomotor symptoms (hot flushes and night sweats), which often peak and gradually subside over a few years, GSM is progressive and chronic—it rarely resolves without targeted, ongoing intervention.

Evidence-Based Treatment Options

Clinical practice guidelines from major medical societies establish a clear continuum of non-hormonal and hormonal treatments tailored to symptom severity.

1. Local Vaginal Estrogen Therapy

For moderate to severe GSM, low-dose local vaginal estrogen (available in creams, dissolving tablets, soft-gel inserts, or flexible silastic rings) is considered the gold-standard medical therapy. Applied directly to the vagina, it restores epithelial thickness, replenishes lactobacilli, restores acidic pH, and re-establishes urethral mucosal coaptation.

Because the dose is minimal and localized, systemic absorption is negligible for most women, meaning local vaginal estrogen does not require opposing progestin therapy in women with an intact uterus. Clinical trials show that local vaginal estrogen can reduce the recurrence of urinary tract infections by more than 50% to 60% in postmenopausal women.

2. Non-Hormonal Moisturizers and Lubricants

For women who prefer non-hormonal options or those with hormone-receptor-positive breast cancer under specific oncological care:

3. Pelvic Floor Physical Therapy for Menopause

Hormonal changes frequently interact with pelvic biomechanics. In response to vaginal dryness and painful intercourse, the pelvic floor muscles often develop involuntary, protective hypertonic spasms (guarding). A pelvic health physical therapist can perform internal myofascial release to relieve muscle tension while prescribing targeted strengthening exercises to combat age-related muscle sarcopenia.

Reputable Medical References and Guidelines

• The Menopause Society (formerly NAMS): The 2020 Genitourinary Syndrome of Menopause Position Statement. Comprehensive consensus on terminology, diagnosis, and evidence-based safety and efficacy of local hormonal and non-hormonal therapies. (menopause.org)
• Endocrine Society Clinical Practice Guideline: Treatment of Symptoms of the Menopause. Guidelines for individualized hormone therapy evaluation and safety parameters. (endocrine.org)
• American College of Obstetricians and Gynecologists (ACOG Clinical Practice Advisory): Practical clinical protocols on treating GSM and managing recurrent urinary tract infections in perimenopausal and postmenopausal populations. (acog.org)
• International Menopause Society (IMS): Global consensus recommendations on menopausal hormone therapy and healthy aging. (imsociety.org)